{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:33:53Z","timestamp":1793115233960,"version":"4.5.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Over the past decades, the therapeutic landscape of nephrology has been transformed by the expanding use of immunosuppressive therapies, reflecting major advances in our understanding of the roles of the innate and adaptive immune systems in the pathogenesis of kidney diseases. While B-cell depletion via rituximab or obinutuzumab has improved immune-mediated kidney disease management, these agents remain insufficient. They spare long-lived plasma cells, memory B cells, and innate effectors, permitting persistent antibody production and ongoing tissue injury. Consequently, increasing attention has focused on anticluster of differentiation 38 (CD38) monoclonal antibodies, including daratumumab, isatuximab, and felzartamab, which target several of these pathogenic immune cell populations. Early clinical experience and emerging trial data in diseases such as immunoglobulin A nephropathy, primary membranous nephropathy, and, most notably, kidney transplantation have suggested potential benefits in selected settings, further supporting their potential role in nephrology. In this narrative review, we summarize the current understanding of the pathophysiological role of CD38-expressing immune cells in kidney diseases and critically evaluate the available clinical evidence on the use of anti-CD38 monoclonal antibody therapies across a spectrum of renal disorders. The review also compares the roles of anti-CD38 monoclonal therapies in native kidney disease and antibody-mediated rejection, since they differ in mechanism, clinical evidence, and treatment options.<\/jats:p>","DOI":"10.1093\/ndt\/gfag238","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:54:27Z","timestamp":1792065267000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[{"name":"University School of Medicine Division of Nephrology, Department of Medicine, Ko\u00e7 , Istanbul ,","place":["Turkiye"]},{"name":"Munci Kalayoglu Organ Transplant Center, Koc University Hospital , Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[{"name":"University School of Medicine Department of Medicine, Ko\u00e7 , Istanbul ,","place":["Turkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Gulmaliyev","sequence":"additional","affiliation":[{"name":"University School of Medicine Department of Medicine, Ko\u00e7 , Istanbul ,","place":["Turkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can C","family":"S\u00fcsal","sequence":"additional","affiliation":[{"name":"Klinikum Stuttgart - Katharinenhospital Department of Nephrology, , Stuttgart ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2521-8201","authenticated-orcid":false,"given":"Caner","family":"S\u00fcsal","sequence":"additional","affiliation":[{"name":"Transplant Immunology Research Center of Excellence TIREX, Ko\u00e7 University School of Medicine , Istanbul ,","place":["Turkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[{"name":"Nephrology Clinic, Dialysis and Renal Transplant Center-\u2018C.I. Parhon\u2019 University Hospital and \u2018Grigore T. Popa\u2019 University of Medicine , Iasi ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Altindal","sequence":"additional","affiliation":[{"name":"Ko\u00e7 University School of Medicine Division of Nephrology, Department of Medicine, , Istanbul ,","place":["Turkiye"]},{"name":"Munci Kalayoglu Organ Transplant Center, Koc University Hospital , Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026102710555853900_bib1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1146\/annurev-immunol-090122-045843","article-title":"Immunology of kidney disease","volume":"42","author":"Foresto-Neto","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"2026102710555853900_bib2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/cei.13119","article-title":"The role of the immune system in kidney disease","volume":"192","author":"Tecklenborg","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"2026102710555853900_bib3","doi-asserted-by":"publisher","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"2026102710555853900_bib4","doi-asserted-by":"publisher","first-page":"1382977","DOI":"10.3389\/fimmu.2024.1382977","article-title":"Application of CD38 monoclonal antibody in kidney disease","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"2026102710555853900_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van\u00a0de\u00a0Donk","year":"2018","journal-title":"Blood"},{"key":"2026102710555853900_bib6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2026102710555853900_bib7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"2026102710555853900_bib8","doi-asserted-by":"publisher","first-page":"108733","DOI":"10.1016\/j.celrep.2021.108733","article-title":"Plasma cell dynamics in the bone marrow niche","volume":"34","author":"Benet","year":"2021","journal-title":"Cell Rep"},{"key":"2026102710555853900_bib9","doi-asserted-by":"publisher","first-page":"101726","DOI":"10.1016\/j.trim.2022.101726","article-title":"Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture","volume":"75","author":"Mujtahedi","year":"2022","journal-title":"Transpl Immunol"},{"key":"2026102710555853900_bib10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"2026102710555853900_bib11","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.4049\/jimmunol.1501761","article-title":"early emergence of CD19-negative human antibody-secreting cells at the plasmablast to plasma cell transition","volume":"198","author":"Arumugakani","year":"2017","journal-title":"J Immunol"},{"key":"2026102710555853900_bib12","doi-asserted-by":"publisher","first-page":"106468","DOI":"10.1016\/j.ekir.2026.106468","article-title":"Prospective cohort study of felzartamab in rituximab-resistant primary membranous nephropathy","volume":"11","author":"Trillini","year":"2026","journal-title":"Kidney Int Rep"},{"key":"2026102710555853900_bib13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.kint.2025.12.026","article-title":"Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA(+)\u03b27(+) cells in IgA nephropathy","volume":"109","author":"Liu","year":"2026","journal-title":"Kidney Int"},{"key":"2026102710555853900_bib14","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1681\/ASN.2021081086","article-title":"Galactose-deficient IgA1 B cells in the circulation of IgA nephropathy patients carry preferentially lambda light chains and mucosal homing receptors","volume":"33","author":"Zachova","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026102710555853900_bib15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ndt\/gfae173","article-title":"IgA class-switched CD27-CD21+ B cells in IgA nephropathy","volume":"40","author":"Popova","year":"2025","journal-title":"Nephrol Dial Transpl"},{"key":"2026102710555853900_bib16","doi-asserted-by":"publisher","first-page":"14343","DOI":"10.3389\/ti.2025.14343","article-title":"Targeting CD38 in antibody-mediated rejection","volume":"38","author":"Mayer","year":"2025","journal-title":"Transpl Int"},{"key":"2026102710555853900_bib17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"2026102710555853900_bib18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2025.2463092","article-title":"CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation","volume":"34","author":"Mayer","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"2026102710555853900_bib19","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.ekir.2024.06.018","article-title":"Phase 1b\/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy","volume":"9","author":"Rovin","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026102710555853900_bib20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"},{"key":"2026102710555853900_bib21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102710555853900_bib22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1053\/j.ajkd.2022.11.010","article-title":"Daratumumab use prior to kidney transplant and T cell-mediated rejection: a case report","volume":"81","author":"Scalzo","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2026102710555853900_bib23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"2026102710555853900_bib24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1053\/j.seminoncol.2021.11.002","article-title":"Current and prospective antibody-based therapies in multiple myeloma","volume":"49","author":"Bryer","year":"2022","journal-title":"Semin Oncol"},{"key":"2026102710555853900_bib25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J Immunol"},{"key":"2026102710555853900_bib26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"2026102710555853900_bib27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de\u00a0Weers","year":"2011","journal-title":"J Immunol"},{"key":"2026102710555853900_bib28","doi-asserted-by":"publisher","first-page":"ii55","DOI":"10.1093\/ckj\/sfaf283","article-title":"One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection","volume":"18","author":"Eti\u00e8ve","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026102710555853900_bib29","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026102710555853900_bib30","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"2026102710555853900_bib31","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/cells8121522","article-title":"Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab","volume":"8","author":"Martin","year":"2019","journal-title":"Cells"},{"key":"2026102710555853900_bib32","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2026102710555853900_bib33","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 Clinical Practice Guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"2026102710555853900_bib34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102710555853900_bib35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N Engl J Med"},{"key":"2026102710555853900_bib36","doi-asserted-by":"publisher","first-page":"106518","DOI":"10.1016\/j.ekir.2026.106518","article-title":"Anti-CD38 therapy with daratumumab in high-risk IgA nephropathy","volume":"11","author":"Poux","year":"2026","journal-title":"Kidney Int Rep"},{"key":"2026102710555853900_bib37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/biom11040513","article-title":"Mechanisms of primary membranous nephropathy","volume":"11","author":"Gu","year":"2021","journal-title":"Biomolecules"},{"key":"2026102710555853900_bib38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/ndt\/gfad225","article-title":"Membranous nephropathy treatment standard","volume":"39","author":"Radhakrishnan","year":"2024","journal-title":"Nephrol Dial Transpl"},{"key":"2026102710555853900_bib39","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ekir.2019.12.006","article-title":"Rituximab in Patients with phospholipase A2 receptor-associated membranous nephropathy and severe CKD","volume":"5","author":"Hanset","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026102710555853900_bib40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study","volume":"33","author":"Cravedi","year":"2011","journal-title":"Am J Nephrol"},{"key":"2026102710555853900_bib41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40265-023-01855-y","article-title":"Update on the application of monoclonal antibody therapy in primary membranous nephropathy","volume":"83","author":"Deng","year":"2023","journal-title":"Drugs"},{"key":"2026102710555853900_bib42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/CCO.0000000000000107","article-title":"Obinutuzumab: a new class of anti-CD20 monoclonal antibody","volume":"26","author":"Gagez","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"2026102710555853900_bib43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"2026102710555853900_bib44","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fimmu.2022.805697","article-title":"New and old anti-CD20 monoclonal antibodies for nephrotic syndrome. Where we are?","volume":"13","author":"Basu","year":"2022","journal-title":"Front Immunol"},{"key":"2026102710555853900_bib45","doi-asserted-by":"publisher","first-page":"108635","DOI":"10.1016\/j.intimp.2022.108635","article-title":"Novel treatment options in rituximab-resistant membranous nephropathy patients","volume":"107","author":"Ahmadian","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2026102710555853900_bib46","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41573-025-01242-0","article-title":"Advances in the treatment of systemic lupus erythematosus","volume":"24","author":"Scherlinger","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026102710555853900_bib47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026102710555853900_bib48","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"Clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","author":"KDIGO 2024.","year":"2024","journal-title":"Kidney Int"},{"key":"2026102710555853900_bib49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10238-025-02014-1","article-title":"Refractory lupus nephritis: current understanding and emerging treatment strategies","volume":"26","author":"Ding","year":"2025","journal-title":"Clin Exp Med"},{"key":"2026102710555853900_bib50","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/ckj\/sfad055","article-title":"Diagnosis and treatment of lupus nephritis: a summary of the consensus document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)","volume":"16","author":"Rojas-Rivera","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026102710555853900_bib51","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/art.41703","article-title":"Molecular signatures of kidney antibody-secreting cells in lupus patients with active nephritis upon immunosuppressive therapy","volume":"73","author":"Crickx","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026102710555853900_bib52","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41591-025-03653-3","article-title":"Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies","volume":"31","author":"Diebold","year":"2025","journal-title":"Nat Med"},{"key":"2026102710555853900_bib53","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"2026102710555853900_bib54","doi-asserted-by":"publisher","first-page":"103520","DOI":"10.1016\/j.jaut.2025.103520","article-title":"Daratumumab monotherapy reverses the immune and pro-fibrotic profiles in refractory lupus nephritis patients: a pilot case study","volume":"158","author":"Roccatello","year":"2026","journal-title":"J Autoimmun"},{"key":"2026102710555853900_bib55","doi-asserted-by":"publisher","first-page":"1525892","DOI":"10.3389\/fimmu.2025.1525892","article-title":"Case report: single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis","volume":"16","author":"Chiarenza","year":"2025","journal-title":"Front Immunol"},{"key":"2026102710555853900_bib56","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"2026102710555853900_bib57","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026102710555853900_bib58","doi-asserted-by":"publisher","first-page":"e14320","DOI":"10.1111\/ctr.14320","article-title":"Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: a systematic review","volume":"35","author":"Hart","year":"2021","journal-title":"Clin Transpl"},{"key":"2026102710555853900_bib59","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/ndt\/gfaf097","article-title":"Antibody-mediated rejection-treatment standard","volume":"40","author":"B\u00f6hmig","year":"2025","journal-title":"Nephrol Dial Transpl"},{"key":"2026102710555853900_bib60","author":"Administration FaD"},{"key":"2026102710555853900_bib61","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1016\/j.ekir.2025.07.009","article-title":"Anti-CD38 daratumumab treatment of chronic active antibody-mediated kidney allograft rejection","volume":"10","author":"Lye","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026102710555853900_bib62","doi-asserted-by":"publisher","first-page":"sfaf219","DOI":"10.1093\/ckj\/sfaf219","article-title":"Desensitization in HLA-incompatible kidney transplant recipients: current strategies and emerging perspectives","volume":"18","author":"Altindal","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026102710555853900_bib63","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/TP.0000000000004279","article-title":"Desensitization in crossmatch-positive kidney transplant candidates","volume":"107","author":"Noble","year":"2023","journal-title":"Transplantation"},{"key":"2026102710555853900_bib64","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1016\/j.ekir.2024.08.020","article-title":"open-label phase 1\/2 study of daratumumab-based desensitization before kidney transplantation","volume":"9","author":"Pilon","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026102710555853900_bib65","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1681\/ASN.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant","volume":"35","author":"Vincenti","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026102710555853900_bib66","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ajt.2024.08.004","article-title":"Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates","volume":"25","author":"Torija","year":"2025","journal-title":"Am J Transpl"},{"key":"2026102710555853900_bib67","doi-asserted-by":"publisher","first-page":"1087597","DOI":"10.3389\/fimmu.2022.1087597","article-title":"Case report: daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"2026102710555853900_bib68","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"key":"2026102710555853900_bib69","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026102710555853900_bib70","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ajt.2023.12.010","article-title":"Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis","volume":"24","author":"Angeletti","year":"2024","journal-title":"Am J Transpl"},{"key":"2026102710555853900_bib71","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ekir.2024.04.006","article-title":"Combined rituximab and daratumumab treatment in difficult-to-treat nephrotic syndrome cases","volume":"9","author":"Angeletti","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026102710555853900_bib72","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.ajt.2024.06.010","article-title":"Rescue with obinutuzumab and daratumumab as combined B cell\/plasma cell targeting approach in severe posttransplant focal segmental glomerulosclerosis recurrence","volume":"24","author":"Randone","year":"2024","journal-title":"Am J Transpl"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag238\/71969998\/gfag238.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag238\/71969998\/gfag238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:57:01Z","timestamp":1793113021000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag238\/8917820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":72,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag238","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"gfag238"}}